Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1152/physrev.00020.2020 http://scihub22266oqcxt.onion/10.1152/physrev.00020.2020 32496872!7347954!32496872     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32496872&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32496872.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Physiol+Rev 2020 ; 100 (4): 1455-1466 Nephropedia Template TP {{tp|p=32496872|t=2020. SARS-CoV-2 and COVID-19: From the Bench to the Bedside |pdf=|usr=}}{{32496872}} gab.com Text SARS-CoV-2 and COVID-19: From the Bench to the Bedside JO: Physiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=32496872 #FOAvip First isolated in China in early 2020, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the novel coronavirus responsible for the ongoing pandemic of Coronavirus Disease 2019 (COVID-19). The disease has been spreading rapidly across the globe, with the largest burden falling on China, Europe, and the United States. COVID-19 is a new clinical syndrome, characterized by respiratory symptoms with varying degrees of severity, from mild upper respiratory illness to severe interstitial pneumonia and acute respiratory distress syndrome, aggravated by thrombosis in the pulmonary microcirculation. Three main phases of disease progression have been proposed for COVID-19: an early infection phase, a pulmonary phase, and a hyperinflammation phase. Although current understanding of COVID-19 treatment is mainly derived from small uncontrolled trials that are affected by a number of biases, strong background noise, and a litany of confounding factors, emerging awareness suggests that drugs currently used to treat COVID-19 (antiviral drugs, antimalarial drugs, immunomodulators, anticoagulants, and antibodies) should be evaluated in relation to the pathophysiology of disease progression. Drawing upon the dramatic experiences taking place in Italy and around the world, here we review the changes in the evolution of the disease and focus on current treatment uncertainties and promising new therapies. Twit Text FOAVip SARS-CoV-2 and COVID-19: From the Bench to the Bedside ????Physiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=32496872 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32496872 #FOAvip English Wikipedia <ref>{{Cite pmid|32496872}}</ref> SARS-CoV-2 and COVID-19: From the Bench to the Bedside #MMPMID32496872 Romagnoli S; Peris A; De Gaudio AR; Geppetti P Physiol Rev 2020[Oct]; 100 (4): 1455-1466 PMID32496872show ga First isolated in China in early 2020, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the novel coronavirus responsible for the ongoing pandemic of Coronavirus Disease 2019 (COVID-19). The disease has been spreading rapidly across the globe, with the largest burden falling on China, Europe, and the United States. COVID-19 is a new clinical syndrome, characterized by respiratory symptoms with varying degrees of severity, from mild upper respiratory illness to severe interstitial pneumonia and acute respiratory distress syndrome, aggravated by thrombosis in the pulmonary microcirculation. Three main phases of disease progression have been proposed for COVID-19: an early infection phase, a pulmonary phase, and a hyperinflammation phase. Although current understanding of COVID-19 treatment is mainly derived from small uncontrolled trials that are affected by a number of biases, strong background noise, and a litany of confounding factors, emerging awareness suggests that drugs currently used to treat COVID-19 (antiviral drugs, antimalarial drugs, immunomodulators, anticoagulants, and antibodies) should be evaluated in relation to the pathophysiology of disease progression. Drawing upon the dramatic experiences taking place in Italy and around the world, here we review the changes in the evolution of the disease and focus on current treatment uncertainties and promising new therapies. |*Betacoronavirus[MESH] |Antimalarials/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/drug therapy/*pathology/*virology[MESH] |Global Health[MESH] |Humans[MESH] |Immunologic Factors/therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/drug therapy/*pathology/*virology[MESH]SARS-CoV-2 and COVID-19: From the Bench to the Bedside (epmc).pdf DeepDyve Pubget Overpricing